TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25064437
Drug: Peginterferon lambda-1a
Normalized name: Peginterferon lambda-1a
DrugBank: Peginterferon lambda-1a (DB14767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon lambda-1a (Lambda) 180 μg
Study: 25064437
Drug: Peginterferon lambda-1a
Normalized name: Peginterferon lambda-1a
DrugBank: Peginterferon lambda-1a (DB14767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon lambda-1a (Lambda) 240 μg
Study: 19524176
Drug: Hypertensive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertensive group pre-treatment
Study: 17925066
Drug: Short-acting β2-agonist
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting β2-agonist (albuterol)
Study: 17925066
Drug: Long-acting β2-agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting β2-agonists
Study: 3132428
Drug: sustained-release buccal
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sustained-release buccal nitroglycerin (2.5 mg, given 8-hourly)
Study: 29051184
Drug: Hydroxyurea (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (20 ± 2.5 mg/kg per day for 12 months)
Study: 26475802
Drug: Crystalloid (Ringers‐acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid (Ringers‐acetate 20 ml kg(‐1), n=15)
Study: 26475802
Drug: Colloid (Venofundin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid (Venofundin 10 ml kg(‐1), n=15)
Study: 17192501
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablet containing 15 mg of pioglitazone plus 850 mg metformin (fed state)
Study: 17192501
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablet (fed state)
Study: 9727512
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dorzolamide and latanoprost
Study: 28552240
Drug: Subcutaneous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous nitroglycerin plus diltiazem (drug treatment group)
Study: 18226672
Drug: EAMD+OC (triphasic
Approvals — FDA: no, EMA: no, PMDA: no
Description: EAMD+OC (triphasic OC containing 180‐250 mcg norgestimate/25 mcg ethinyl estradiol)
Study: 9324339
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate, cytarabine, coordinated intrathecal chemotherapy)
Study: 3027601
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (20 mg X 3)
Study: 18936595
Drug: Occlusal splint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusal splint (OS) therapy
Study: 21946400
Drug: Sham laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham laser therapy
Study: 12842988
Drug: New prognostic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New prognostic score based on median expression ratio after consolidation therapy and 75th percentile of expression ratio at diagnosis
Study: 12842988
Drug: High levels
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High levels of fusion gene expression at diagnosis or less than 3 logs of tumor reduction during the first 3 to 4 months of therapy
Study: 8741364
Drug: 1 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/day calcium lactate for 10 months (control)
Study: 1430999
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (beta-lactam and aminoglycoside)
Study: 14582817
Drug: Diphenhydramine, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine, 50 mg
Study: 4008809
Drug: Cyproheptadine, 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproheptadine, 16 mg
Study: 4008809
Drug: Hydroxyzine, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine, 75 mg per day for 3 weeks
Study: 9862082
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg haloperidol
Study: 989370
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg haloperidol
Study: 12483184
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy with streptokinase (250,000 units bolus followed by 100,000 units/hr, max 4,000,000 units)
Study: 9891197
Drug: RW94 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: RW94 (5 grams administered orally after each main meal)
Study: 8193507
Drug: Dicyclomine hydrochloride
Normalized name: Dicyclomine Hydrochloride
DrugBank: Dicyclomine (DB00804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dicyclomine hydrochloride 3 mg/kg/day
Study: 8193507
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment (dicyclomine)
Study: 2454355
Drug: 5 or
Normalized name: Acys-5 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 or 10 mg carvedilol once daily for 3 to 7 days, increased to 20 mg daily if BP reduction was insufficient
Study: 27875516
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of trastuzumab treatment
Study: 8334339
Drug: Baoshen Pill
Normalized name: Banophen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baoshen Pill (Rheum palmatum extract, RPE)
Study: 8751804
Drug: Oral Tegafur
Normalized name: tegafur
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Oral Tegafur (Group B)
Study: 19875605
Drug: Autologous umbilical
Normalized name: Autologous umbilical cord blood
DrugBank: Autologous cord blood (DB17926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous umbilical cord blood infusion
Study: 22224244
Drug: Ceraxon (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceraxon (2 g daily for 10 days)
Study: 8737134
Drug: Sparfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin (400 mg loading dose on day 1 followed by 200 mg once daily for pneumonia; 200 mg loading dose on day 1 followed by 100 mg daily for COPD)
Study: 8737134
Drug: Comparator regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator regimens (amoxycillin/clavulanic acid 500/125 mg tid, amoxycillin 1000 mg tid, amoxycillin 1000 mg tid plus ofloxacin 200 mg bid, erythromycin 1000 mg bid)
Study: 1577399
Drug: Etomoxir 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomoxir 50 mg
Study: 25261884
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (treatment as usual)
Study: 11792161
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment with levetiracetam (individualized, 500-1000 mg twice daily for 8 weeks)
Study: 28695267
Drug: AAFP 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAFP 500 mg with methylprednisolone (4 mg twice daily)
Study: 28695267
Drug: OAA 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAA 1000 mg with prednisone (5 mg twice daily)
Study: 1621888
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg/day)
Study: 7634283
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment to achieve blood pressure levels below 85 mmHg
Study: 2454357
Drug: Carvedilol 50
Normalized name: carvedilol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 50 mg, administered orally, single and twice daily regimen
Study: 25792708
Drug: BET 2×1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BET 2×1 mg/day (BET1, n=19)
Study: 25792708
Drug: BET 2×2
Approvals — FDA: no, EMA: no, PMDA: no
Description: BET 2×2 mg/day (BET2, n=19)
Study: 7986242
Drug: Effervescent tablet
Normalized name: Pain Relief Effervescent Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent tablet
Study: 15381895
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.5 mg/kg
Study: 11931601
Drug: Intact Metadate
Normalized name: Metadate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intact Metadate CD capsules
Study: 28645284
Drug: Established CVD
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Established CVD not receiving guideline-recommended treatment prior to the trial
Study: 21493010
Drug: Clonidine (α2-adrenoceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (α2-adrenoceptor agonist, intravenous infusion)
Study: 19723122
Drug: Tonabersat 15
Normalized name: Tonabersat
DrugBank: Tonabersat (DB06578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonabersat 15 mg
Study: 19723122
Drug: Tonabersat 40
Normalized name: Tonabersat
DrugBank: Tonabersat (DB06578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonabersat 40 mg
Study: 10475318
Drug: Intravenous dextromethorphan
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous dextromethorphan 5 mg/kg before anesthetic induction (Pre group)
Study: 2220663
Drug: Surgery and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery and radiation therapy
Study: 28074475
Drug: LPS injection
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS injection (0.4 or 0.8 ng/kg)
Study: 24941951
Drug: Fiber-enriched orange
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber-enriched orange juice (400 mL for 21 days)
Study: 24941951
Drug: Placebo orange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orange juice (400 mL for 21 days)
Study: 21663648
Drug: 45 g
Normalized name: SODIUM CHLORIDE 0.045 g in 5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 g milk fat/d from test butter and cheese with 0.24 wt% phytanic acid
Study: 30078537
Drug: Basic saline
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic saline solution (Control)
Study: 24356636
Drug: Conventional tri-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tri-weekly paclitaxel and carboplatin (c-TC)
Study: 22629129
Drug: Intravenous anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthesia (Anesthesia Group, AG)
Study: 20080382
Drug: Paracetamol 500
Normalized name: Paracetamol 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 500 mg, Caffeine 50 mg, Opium 25 mg
Study: 20080382
Drug: Paracetamol 500
Normalized name: Paracetamol 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 500 mg, Caffeine 50 mg, Opium 50 mg
Study: 21640574
Drug: Tramadol 100
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 100 mg
Study: 15378234
Drug: Permacol injection
Normalized name: lidocaine hydrochloride Topical Spray [Dermacool]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permacol injection
Study: 19013613
Drug: Macroplastique injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macroplastique injection
Study: 10710824
Drug: New microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: New microemulsion formulation of cyclosporine
Study: 1838749
Drug: OPC‐7251 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC‐7251 1% cream
Study: 22624993
Drug: Cream base
Normalized name: Cream Base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream base
Study: 7015173
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (LDH) injected subcutaneously in the contralateral thigh
Study: 7015173
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (LDH) injected subcutaneously in the contralateral abdominal skin-fold
Study: 28217880
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation therapy (CRT) and treatment as usual (TAU)
Study: 7883848
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg iodine
Study: 7883848
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg iodine
Study: 7883848
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg iodine
Study: 1453217
Drug: Lupin protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupin protein at 0.8 g/(kg.d)
Study: 1453217
Drug: Lupin protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupin protein at 0.6 g/(kg.d)
Study: 1453217
Drug: Lupin protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupin protein at 0.4 g/(kg.d)
Study: 1453217
Drug: Egg protein
Normalized name: Egg protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg protein at 0.6 g/(kg.d)
Study: 1453217
Drug: Egg protein
Normalized name: Egg protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg protein at 0.45 g/(kg.d)
Study: 6366810
Drug: Co-trimoxazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (400 mg sulphamethoxazole plus 80 mg trimethoprim)
Study: 26912543
Drug: Tolvaptan (45/15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (45/15, 60/30, or 90/30 mg daily as tolerated)
Study: 14617323
Drug: Continuous IV
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous IV infusion of calcium-gluconate at a dose of 1.8 mmol calcium per hour
Study: 14617323
Drug: Continuous IV
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous IV infusion of calcium-gluconate
Study: 29080061
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy
Study: 3114302
Drug: Bromocriptine (BCT;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (BCT; 3.75 mg/day; n = 14)
Study: 23019944
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (RTT)
Study: 18055726
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1,000 mg) and Vitamin E (400 International Units)
Study: 16126331
Drug: InCare Advance
Approvals — FDA: no, EMA: no, PMDA: no
Description: InCare Advance Plus (gel-lubricated uncoated catheter)
Study: 19318455
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen (TD E2)
Study: 11599198
Drug: Spironolactone with
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone with ACE-inhibitor
Study: 11599198
Drug: ACE-inhibitor
Normalized name: C1-inhibiting factor
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-inhibitor
Study: 11599198
Drug: Spironolactone and
Normalized name: Spironolactone and torsemide only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone and ACE-inhibitor
Study: 9394235
Drug: Faropenem (FRPM)
Normalized name: Meropenem
DrugBank: Faropenem (DB12190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Faropenem (FRPM) in combination with Enteronon-R (E-group)
Study: 8424507
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (EM) 100 micrograms/kg
Study: 8874561
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (EM)
Study: 8424507
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (IM)
Study: 5072238
Drug: +/- propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: +/- propranolol (120 mg)
Study: 22956408
Drug: intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous immunoglobulin (IVIG, 0.4 g/kg/day for 5 days)
Study: 18704101
Drug: Active TMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active TMS (transcranial magnetic stimulation) administered to the left dorsolateral prefrontal cortex at 10 pulses per second, 120% of motor threshold, for a total of 3000 pulses per day
Study: 24081023
Drug: Raloxifene (RLX)
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene (RLX) 60 mg/day
Study: 15295352
Drug: Slow-dose escalation
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-dose escalation (SDE)
Study: 11330366
Drug: Regional antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional antimicrobial prophylaxis (teicoplanin 400 mg)
Study: 11330366
Drug: Perioperative antibiotic
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative antibiotic prophylaxis (teicoplanin 800 mg)
Study: 26622463
Drug: 5% 5-ALA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% 5-ALA for 1.5 h followed by three 20-min doses of infrared radiation once a week for 3 weeks
Study: 23463180
Drug: Telephone-assisted parent-administered
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-assisted parent-administered behavioural intervention (bibliotherapy)
Study: 18000162
Drug: Atorvastatin (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (n = 19)
Study: 11393383
Drug: Spirapril 6
Normalized name: spirapril 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril 6 mg daily
Study: 2859256
Drug: Alprazolam (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (1.2 mg/day)
Study: 27429618
Drug: Conventional periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional periodontal therapy
Study: 30807279
Drug: .00 g/dl
Approvals — FDA: no, EMA: no, PMDA: no
Description: .00 g/dl alcohol dose
Study: 9426022
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg three times daily without NTG
Study: 29985079
Drug: One-step approach
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-step approach (75-g glucose load, fasting, 1h, and 2h measurements)
Study: 29985079
Drug: Two-step approach
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two-step approach (50-g glucose load followed by 100-g glucose load if necessary)
Study: 28028994
Drug: Genexol-PM (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genexol-PM (300 mg/m², once every 3 weeks) + carboplatin (AUC 5)
Study: 28028994
Drug: Genexol-PM (220
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genexol-PM (220 mg/m², once every 3 weeks) + carboplatin (AUC 5)
Study: 26352813
Drug: Sebelipase alfa
Normalized name: Sebelipase alfa
DrugBank: Sebelipase alfa (DB11563)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sebelipase alfa (1 mg/kg, intravenously, every other week)
Study: 23345000
Drug: Oral CP-4126
Normalized name: CP
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral CP-4126 (100-3000 mg/day)
Study: 23345000
Drug: Oral CP-4126
Normalized name: CP
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral CP-4126
Study: 19882058
Drug: Ropivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 7.5 mg plus 25 ug of fentanyl
Study: 16758644
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of bone marrow mononuclear cells
Study: 7661066
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antiarrhythmic therapy)
Study: 19272057
Drug: Quinidine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine therapy
Study: 7001961
Drug: Flunisolide (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunisolide (inhaled steroid)
Study: 31715161
Drug: Broad-spectrum combination
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum combination empiric antibiotics
Study: 21044166
Drug: Implant-cantilever group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-cantilever group (1 implant with cantilever)
Study: 17531578
Drug: Candesartan 8
Normalized name: candesartan 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8 mg/day for 3 to 6 weeks before and 16 mg/day for 6 months after electrical cardioversion
Study: 15768732
Drug: Probiotics (1.2g/d)
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (1.2g/d) and soluble fiber (11g/d) with L-Glutamine (30g/d) if diarrhea persisted at week 4
Study: 8446846
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg
Study: 2737271
Drug: Formoterol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (12 micrograms twice daily)
Study: 2737271
Drug: Salbutamol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (200 micrograms twice daily)
Study: 27939076
Drug: Simtuzumab (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simtuzumab (125 mg/mL, subcutaneously once a week)
Study: 21303934
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy (PST) delivered via videophones
Study: 12622106
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion of propofol combined with midazolam
Study: 8983891
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with FEM (specifically for histologic grade III tumors)
Study: 6751510
Drug: gentamicin-betamethasone ointment
Normalized name: betamethasone / gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: gentamicin-betamethasone ointment
Study: 23397347
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin A (7500 μg) once a week
Study: 19809026
Drug: Intravenous infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusions of Fe(III)-hydroxide sucrose (400 mg) after venesection